ATHE Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 5.21%, SMA50 7.38%, SMA200 -14.69%). The stock’s 14-day RSI is 57.94 (neutral), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.56% below its high and over 40.07% above its low. Average 10-day trading volume of 17.39 thousand shares is below the 3-month average of 50.81 thousand, indicating normal recent market interest.

Alterity Therapeutics Limited has 18.13 million shares outstanding. The public float is 288.05 thousand shares, elevated short interest at 0.22% of float. This equals 38.98 thousand shares. The short ratio is 0.38 days. Institutional investors hold 1.78% of the float. Insiders own 0.0%.

Alterity Therapeutics Limited generated EPS of -$0.74 over the past year. Five-year average earnings growth is 34.33%. Wall Street analysts project EPS growth of 31.66% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $10.00. The high target offers 221.29% upside. The low target suggests 100.8% downside. The mean target is $13.00. This offers 161.04% upside. Alterity Therapeutics Limited earnings surprise history is a mixed track record. The quarter that ended February 25, 2026, missed forecasts by 65.91%. The prior quarter beat by -7.21%. Over the last six quarters, Apple has recorded several small beats. These include -97.53% in February 28, 2024.

Alterity Therapeutics Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

Alterity Therapeutics Limited (NASDAQ:ATHE) closed at $4.72 USD, losing -$0.26 (-5.12%) from the previous close of $4.98. The stock is currently mid-range between its 52-week high and low $2.66 and $7.00. With a market capitalization of about $42.83 million, Alterity Therapeutics Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.03). Key stats such as the average daily volume over the past year has been around 49.90 thousand shares, volume is running light vs its 52-week average. Headquartered in Melbourne, VIC, Alterity Therapeutics Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO David A. Stamler, the company employs approximately 9 people and listed since September 29, 2003. Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases.

Alterity Therapeutics Limited trades at a P/E ratio of -7.13, slightly below the S&P 500 average, with a price-to-sales ratio of 16.2 and a price-to-book ratio of 2.14 suggesting the stock is closer to book value. The P/FCF stands at -26.36, also below market averages.

Our AI price prediction model suggests that Alterity Therapeutics Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.42%, with price expected at $4.71 by August 04, 2026, within a range of $4.42 to $4.99 3-Month Outlook: Projected rise of 100.6%, reaching $9.99 by October 19, 2026, with a range of $9.62 to $10.48. 1-Year Outlook: Projected gain of 455.82%, with price at $27.68 by July 21, 2027, within a range of $25.20 to $36.36.

Alterity Therapeutics Limited (NASDAQ:ATHE) shares are flat 7.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alterity Therapeutics Limited trading at a premium to the broader market with a P/E of -7.13. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.20, suggesting 124.9% upside. Our AI forecast model points to short-term weakness (-5.42% over two weeks), a medium-term rise (100.6% over three months), and a longer-term gain (455.82% over one year), with expected trading ranges indicating moderate volatility.